10x Genomics (TXG) – Research Analysts’ Weekly Ratings Changes

A number of research firms have changed their ratings and price targets for 10x Genomics (NASDAQ: TXG):

• 11/9/2026 – 10x Genomics had its price target lowered by JPMorgan Chase & Co. from $70.00 to $65.00. They now have a “neutral” rating on the stock.
• 11/9/2026 – 10x Genomics had its price target lowered by Barclays from $110.00 to $70.00. They now have an “overweight” rating on the stock.
• 11/6/2026 – 10x Genomics had its price target lowered by UBS Group from $90.00 to $61.00. They now have a “neutral” rating on the stock.
• 11/6/2026 – 10x Genomics had its price target raised by Stifel Nicolaus from $50.00 to $68.00. They now have a “buy” rating on the stock.
• 11/6/2026 – 10x Genomics had its price target raised by Citigroup from $50.00 to $60.00. They now have a “hold” rating on the stock.
• 10/23/2026 – 10x Genomics was downgraded by Stephens from “overweight” to “equal weight”.
• 10/13/2026 – 10x Genomics was given a new $70.00 price target by Stifel Nicolaus.
• 10/13/2026 – 10x Genomics had its price target raised by TD Cowen from $47.00 to $70.00. They now have a “hold” rating on the stock.
• 10/12/2026 – 10x Genomics had its price target raised by Morgan Stanley from $40.00 to $70.00. They now have an “equal weight” rating on the stock.
• 10/12/2026 – 10x Genomics had its price target raised by Canaccord Genuity Group from $60.00 to $100.00. They now have a “buy” rating on the stock.
• 10/7/2026 – 10x Genomics had its price target raised by Barclays from $52.00 to $110.00. They now have an “overweight” rating on the stock.
• 9/29/2026 – 10x Genomics had its price target raised by Leerink Partners from $40.00 to $90.00. They now have a “market perform” rating on the stock.
• 9/28/2026 – 10x Genomics had its price target raised by Piper Sandler from $47.00 to $80.00. They now have a “neutral” rating on the stock.
• 9/28/2026 – 10x Genomics is now covered by Argus. They set a “buy” rating and a $110.00 price target on the stock.
• 9/21/2026 – 10x Genomics had its “sell (d-)” rating reaffirmed by Weiss Ratings.

10x Genomics Price Performance

NASDAQ:TXG traded down $1.84 during mid-day trading on Friday, reaching $57.26. The stock had a trading volume of 733,557 shares, compared to its average volume of 3,013,892. 10x Genomics has a 12 month low of $15.12 and a 12 month high of $102.81. The stock has a market capitalization of $7.46 billion, a PE ratio of -110.11 and a beta of 2.03. The stock has a 50-day simple moving average of $74.02 and a two-hundred day simple moving average of $42.38.

10x Genomics (NASDAQ:TXG) last released its earnings results on Thursday, November 5th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.12. The firm had revenue of $150.67 million during the quarter, compared to analysts’ expectations of $147.96 million. 10x Genomics had a negative return on equity of 8.19% and a negative net margin of 10.84%. The company’s quarterly revenue was up 1.1% on a year-over-year basis. During the same period in the prior year, the company earned ($0.22) earnings per share. Equities analysts expect that 10x Genomics will post -0.74 EPS for the current year.

Insider Buying and Selling at 10x Genomics

In related news, Director Shehnaaz Suliman sold 5,723 shares of the firm’s stock in a transaction dated Tuesday, September 22nd. The stock was sold at an average price of $81.19, for a total value of $464,650.37. Following the sale, the director directly owned 23,792 shares of the company’s stock, valued at $1,931,672.48. This trade represents a 19.39% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director John Stuelpnagel sold 20,000 shares of 10x Genomics stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $61.75, for a total value of $1,235,000.00. Following the completion of the transaction, the director owned 328,436 shares in the company, valued at approximately $20,280,923. This represents a 5.74% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 159,333 shares of company stock worth $10,655,070 over the last quarter. 8.84% of the stock is currently owned by company insiders.

10x Genomics, Inc. develops technology for studying biological systems at single-cell and spatial resolution. Its instruments, consumables and software help researchers analyze gene expression and other features of cells while preserving information about their location within tissue. The company’s product platforms include Chromium for single-cell analysis, Visium for spatial gene-expression analysis and Xenium for in situ analysis of gene activity within tissue samples. Its tools are used in areas such as immunology, neuroscience, cancer research and drug discovery.